Marshall Edwards Inc - MSHL - reported that the USPTO has issued a new patent, covering a number of the Company’s isoflavone-based compounds, including lead oncology-drug candidates ME-143 and ME-344, and their pharmaceutical compositions

Tags: MSHL CSIQ SLXP PGNX Nasdaq:MSHL Nasdaq:CSIQ Nasdaq:SLXP Nasdaq:PGNX